Does unfavorable early-stage Hodgkin mean advanced-stage disease?

No. It means stage I-II disease has one or more unfavorable risk factors that may change treatment intensity, chemotherapy cycles, radiation use, or PET-adapted strategy.

Why do GHSG, EORTC/LYSA, and NCCN classifications differ?

They were developed in different cooperative group and guideline contexts, with different cutoffs for nodal areas, mediastinal bulk, ESR, B symptoms, age, and extranodal disease.

Can this calculator choose ABVD cycles or radiation dose?

No. It classifies favorable versus unfavorable risk. Treatment selection still requires current protocol guidance, interim PET response, histology confirmation, organ function, fertility goals, and lymphoma specialist judgment.

Clinical Tools

July 3, 2026

OncoToolkit Team

Early-Stage Hodgkin Lymphoma Risk Calculator

Classify stage I-II classical Hodgkin lymphoma as favorable or unfavorable using GHSG, EORTC/LYSA, or NCCN-style criteria.

Evidence-Based Guide

Early-stage Hodgkin lymphoma favorable and unfavorable risk calculator

Quick Navigation

1. What the Calculator Does

The early-stage Hodgkin lymphoma calculator helps classify stage I-II classical Hodgkin lymphoma as favorable or unfavorable. It supports three commonly used definitions: GHSG, EORTC/LYSA, and NCCN-style criteria.

Open the calculator: Early-Stage Hodgkin Lymphoma Risk.

Risk grouping matters because limited-stage Hodgkin lymphoma is highly curable, and treatment is deliberately risk-adapted. A favorable classification may support abbreviated chemotherapy and carefully selected radiation approaches in the right protocol. An unfavorable classification may lead clinicians to consider additional chemotherapy cycles, combined-modality treatment, different radiation fields or doses, or PET-adapted strategies. The classification is a starting point for treatment planning, not the whole plan.¹, ²

Clinical caution

This tool is intended for stage I-II classical Hodgkin lymphoma after appropriate staging. It should not be used to classify advanced-stage disease, nodular lymphocyte predominant Hodgkin lymphoma, or cases where pathology or staging remains uncertain.

2. GHSG vs EORTC/LYSA vs NCCN

The systems share the same clinical goal, but they are not interchangeable. In practice, the right system is usually determined by the guideline, trial, or institutional pathway being followed.

System	Unfavorable if any factor is present	Practical Note
GHSG	Large mediastinal mass, extranodal disease, more than 2 nodal areas, or ESR >50 without B symptoms / >30 with B symptoms	Often used in German Hodgkin Study Group trial framing.
EORTC/LYSA	Large mediastinal mass, age 50 or older, 4 or more nodal areas, or ESR >50 without B symptoms / >30 with B symptoms	Age is an unfavorable factor here, while extranodal disease is not used the same way as GHSG.
NCCN-style	Bulky mediastinal or mass >10 cm, B symptoms, ESR >50, or more than 3 disease sites	Useful when aligning with U.S. guideline-style risk factors.

The OncoToolkit calculator reports the selected system and lists the specific unfavorable factors present. This helps avoid a common documentation problem: writing "early unfavorable" without stating which rule produced that result.

3. Key Inputs

Bulky mediastinal disease or a mass greater than 10 cm
Number of involved nodal areas or disease sites
ESR
B symptoms
Extranodal disease
Age

Input	Where It Comes From	Before You Calculate
Bulk	CT/PET-CT report and mediastinal measurements	Confirm local definition for mediastinal mass ratio versus absolute mass >10 cm.
Nodal areas/sites	Staging imaging and Ann Arbor mapping	Use the definition tied to the selected system; area counts can differ from casual "site" wording.
ESR and B symptoms	Baseline labs and clinical history	ESR thresholds depend on whether B symptoms are present in GHSG and EORTC/LYSA.
Extranodal disease	Staging imaging, pathology, and lymphoma review	Relevant for GHSG classification in this calculator.
Age	Patient demographics	Relevant for EORTC/LYSA classification at age 50 or older.

4. Practical Clinical Workflow

Confirm diagnosis. Ensure classical Hodgkin lymphoma histology and obtain expert hematopathology review when the diagnosis is uncertain.
Complete baseline staging. Use PET-CT/CT, marrow assessment when indicated, labs, and clinical history to confirm stage I-II disease.
Select the classification system before entering data. Choose GHSG, EORTC/LYSA, or NCCN based on the protocol or guideline you plan to follow.
Enter unfavorable factors. Record bulk, nodal areas/sites, ESR, B symptoms, extranodal disease, and age.
Interpret the output alongside PET-adapted treatment strategy. Interim PET response can meaningfully alter subsequent chemotherapy and radiation decisions in many modern pathways.⁴
Document the rule used. For example: "Stage IIA early unfavorable by GHSG due to more than 2 nodal areas and ESR >50 without B symptoms."

Relevant OncoToolkit links include the Early-Stage Hodgkin Lymphoma Risk calculator, IPS Hodgkin Prognostic Score, the hematology calculators hub, and haematology guideline hub.

5. Interpretation Pitfalls

Unfavorable does not mean advanced.

Early unfavorable means stage I-II disease has risk factors associated with higher relapse risk or different treatment requirements. It is distinct from stage III-IV disease.

The systems can disagree.

A 52-year-old patient may be unfavorable by EORTC/LYSA due to age but not by GHSG if no other risk factors are present. The calculator is designed to make that distinction visible.

PET response is not optional context.

Modern limited-stage Hodgkin lymphoma treatment often incorporates interim PET response. Risk grouping should be combined with response-adapted strategy rather than interpreted in isolation.

6. FAQ

Which early Hodgkin risk system should I use?

Use the system specified by the clinical trial, guideline, or institutional protocol being followed. Avoid mixing cutoffs from different systems in the same treatment decision.

Does favorable risk mean no radiation is needed?

No. Favorable risk is one input into treatment planning. Radiation use depends on protocol, disease sites, PET response, patient age, late-effect risks, and shared decision-making.

Can this calculator be used after relapse?

No. It is intended for baseline limited-stage classification, not relapsed/refractory Hodgkin lymphoma risk assessment.

Classify Limited-Stage Hodgkin Risk

Compare GHSG, EORTC/LYSA, and NCCN-style favorable versus unfavorable factors.

Open the Hodgkin Risk Calculator

References

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. PMC
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 2.2020. JNCCN. Source
German Hodgkin Study Group. Disease stages and risk-group information. Source
Management of limited-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2023. Source
Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol. 2013. PubMed

Saved Results